Clinical Trial Update: A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ALTY-0501 for the treatment of dry eye has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• ALTY-0501

Snippet

Sponsor: Alacrity Biosciences, Inc. | Conditions: Dry Eye | Phase 2 | Status: COMPLETED